BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS
Pagina dedicata companiei BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS listata cu simbolul US.BCYC
Descriere companie[edit | ]
Bicycle Therapeutics plc (www.bicycletherapeutics.com) is a clinical-stage biopharmaceutical company that is developing a class of medicines for diseases. The Company is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTC) targeting EphA2, and BT8009, a second-generation BTC targeting Nectin-4, a tumor antigen in company-sponsored Phase I/II trials. In addition, BT1718, a BTC that targets membrane type 1 matrix metalloproteinase (MT1-MMP) is being investigated in an ongoing Phase I/IIa clinical trial sponsored by the center for drug development of cancer research United Kingdom. The Company’s immune-oncology products include BT7480, BT7455 and BT7401. BT7480 is a TICA that targets CD137 and Nectin-4. BT7455 is a TICA targeting EphA2 and CD137. BT7401 is an agonistic Bicycle built from multiple CD137 monomeric Bicycles.
Grafic actiuni companie[edit | ]